ABVC BioPharma, Inc. · NASDAQ:ABVC
ABVC BioPharma — Investor Presentation (February 2022)
15 slides from ABVC BioPharma's investor presentation, February 2022
Slide 1: Corporate Overview Spring 2022
NASDAQ: ABVC Corporate Overview SPRING 2022
Slide 2: Company Overview
NASDAQ: ABVC SPRING 2022 Company Overview ABVC BioPharma licenses promising medical research conducted in the Asia-Pacific region and enlists top-ranked principal investigators in the United States to conduct Phase I and Phase II clinical trials. We specialize in botanically based solutions that del
Slide 3: Business Model
NASDAQ: ABVC SPRING 2022 Business Model ABVC BioPharma develops its pipeline by carefully tracking new medical discoveries and medical device technologies from research institutions in the Asia-Pacific region. We closely examine pre-clinical and animal model studies to identify solutions that ABVC b
Slide 4: Botanicals Specialization
NASDAQ: ABVC SPRING 2022 Botanicals Specialization Over the past decades, herbal medicines from Asia typically exhibit fewer adverse side effects than those derived from animals or synthetic ingredients. Many herbal drugs developed in the West have also been successful in addressing some of our most
Slide 5: Near-term Drug Pipeline
NASDAQ: ABVC SPRING 2022 Near-term Drug Pipeline MEDICAL CONDITION ABVC DRUG PIPELINE STATUS CLINICAL PARTNER GLOBAL MARKET SIZE Stanford University Medical Center, Taipei Major Depressive Disorder (MDD) ABV-1504 Phase II Completed $13.7 Billion (2018)1 Veterans General Hospital Adult Attention Defi
Slide 6: Clinical Trial Principal Investigators
NASDAQ: ABVC SPRING 2022 Clinical Trial Principal Investigators • Major Depressive Disorder (MDD) • Attention Deficit Hyperactivity • Myelodysplastic Syndrome (MDS) Disorder (ADHD) • Solid Tumors • Depression in Cancer Patients • Vitargus® • Triple Negative Breast Cancer • Pancreatic Cancer 6
Slide 7: Medical Devices: Vitargus ABV-1701
MEDICAL DEVICES NASDAQ: ABVC SPRING 2022 Vitargus ABV-1701 ® • Vitreous, gel-like substance that helps the eye maintain a round shape and Choroid keeps the retina in place during and Sclera after retinal re-attachment surgery. Retina • Current vitreous substitutes (air, silicone Cornea oil, octafluo
Slide 8: Medical Devices: Vitargus ABV-1701
MEDICAL DEVICES NASDAQ: ABVC SPRING 2022 Vitargus ABV-1701 ® First-In-Human clinical trials conducted at the Sydney Eye Hospital in Australia have demonstrated that Vitargus: • Provides an immediate improvement in visual acuity after surgery. • Permits a patient to have unrestricted post-surgery mov
Slide 9: Central Nervous System: ABV-1504, ABV-1505
CENTRAL NERVOUS SYSTEM NASDAQ: ABVC SPRING 2022 ABV-1504 Major Depressive Disorder (MDD) ABV-1505 Attention Deficit Hyperactivity Disorder (ADHD) ABV-1601 Depression in Cancer Patients ABV-1504: successfully completed Phase I and Phase II clinical studies for treating MDD. ABV-1505: successfully com
Slide 10: Oncology: ABV-1501, ABV-1703, ABV-1702
ONCOLOGY NASDAQ: ABVC SPRING 2022 ABV-1501 Triple Negative Breast Cancer (TNBC) ABV-1703 Pancreatic Cancer ABV-1702 Myelodysplastic Syndrome (MDS) 1501, 1702 and 1703 have received US FDA IND Approval and are in a Phase II clinical study. • Active ingredient, BLEX-404, derived from the Maitake mushr
Slide 11: Management Team
NASDAQ: ABVC SPRING 2022 Management Team Howard Doong, M.D., Ph. D. Chief Executive Officer Formerly CAP-certified Laboratory Director of Taipei Veteran General Hospital Laboratory of Cancer Genomic Medicine, CEO of Frasergen Genomic Medicine Corp. and Vice President of TrimGen Corporation, a manufa
Slide 12: Management Team
NASDAQ: ABVC SPRING 2022 Management Team Dr. Chi-Hsin Richard King Chief Scientific Officer Formerly Senior Vice President at the pharmaceutical company TaiGen. Formerly Director of the Medicinal Chemistry Department at the drug discovery and manufacturing company Albany Molecular Research Inc., sol
Slide 13: Financial Highlights
NASDAQ: ABVC Financial Highlights (as of September 30, 2021) Paid-in Capital $49,716,411 Cash (Not including exercise of Series A Warrants) $4,449,772 Approximate Burn Rate $500,000 per month Shareholder Equity $7,589,741 Shares Outstanding 27,935,783 Market Cap (as of September 30, 2021) 61,964,000
Slide 14: Growth Strategy 2022
NASDAQ: ABVC SPRING 2022 Growth Strategy 2022 • MDD Phase II clinical study demonstrated material improvement in both efficacy and safety over existing medications available. ABVC will be seeking a Phase III partner in 2022 to demonstrate statistical significance for our MDD results. • Vitargus has
Slide 15: Legal Notice
NASDAQ: ABVC Legal Notice With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of ABVC could differ significantly from those statements. Factors that could c
ABVC BioPharma — Investor Presentation (February 2022) on 6ix